Drug Profile

Mitiglinide/metformin

Alternative Names: Metgluna

Latest Information Update: 08 Oct 2010

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Kissei Pharmaceutical
Developer Elixir Pharmaceuticals
Class Antihyperglycaemics; Biguanides; Isoindoles
Mechanism of Action AMP activated protein kinase stimulants; Potassium channel antagonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No

Highest Development Phases

No development reported Type 2 diabetes mellitus

Most Recent Events

08 Oct 2010 No development reported - Phase-III for Type-2 diabetes mellitus in USA (PO)
21 Nov 2008 Final efficacy and safety data from a phase III trial Type-2 diabetes released by Elixir
28 Mar 2008 Phase-III clinical trials in Type-2 diabetes mellitus in USA (PO)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com